Press Releases

“Measurement of BCMA-EV can thus help in identifying resistance mechanisms and side effects of BCMA targeted therapies in future studies.”

BUFFALO, NY- December 6, 2023 – A new research paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.”

In myeloma patients, high levels of soluble B-cell maturation antigen (sBCMA) can... continue reading >>

“Here, we study the induction of mitochondrial biogenesis by Osteopontin variants in deadherent breast tumor cells.”

BUFFALO, NY- December 4, 2023 – A new research paper was published in Oncotarget's Volume 14 on December 1, 2023, entitled, “Osteopontin induces mitochondrial biogenesis in deadherent cancer cells.”

Metastasizing cells display a unique metabolism, which is very different from the Warburg effect that arises in primary tumors. Over short time frames, oxidative phosphorylation... continue reading >>

“The Achilles’ heel of CRISPR application is the delivery of sgRNA/Cas9 to the desired tissues.”

BUFFALO, NY- November 28, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on November 27, 2023, entitled, “The double-edge sword of CRISPR application for in vivo studies.”

In this new paper, researcher Martin K. Thomsen from Aarhus University begins his editorial by discussing a hallmark paper that was published a decade ago by Platt et al. on the in vivo application of... continue reading >>

“While Ras’s relationship to cancer has been long established [37], it has been considered an undruggable target for many years.”

BUFFALO, NY- November 27, 2023 – A recent review paper was published in Oncotarget's Volume 14 on July 1, 2023, entitled, “Targeting Ras with protein engineering.”

Ras proteins are small GTPases that regulate cell growth and division. Mutations in Ras genes are associated with many types of cancer, making them attractive targets for cancer therapy. Despite... continue reading >>

“Our study may reveal previously uncharacterized population-specific variants that may increase the risk of BC in the Kazakh population.”

BUFFALO, NY- November 22, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “Determination of genetic predisposition to early breast cancer in women of Kazakh ethnicity.”

Breast cancer (BC) is the most common type of cancer among women in Kazakhstan. To date, little data are available on the spectrum of... continue reading >>

“Effectively integrating these rich resources with GWAS results will continue to help prioritize causative inherited genetic variants and improve our molecular understanding of disease etiology [...]”

BUFFALO, NY- November 20, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on August 30, 2023, entitled, “Predicting the molecular functions of regulatory genetic variants associated with cancer.”

Some of inherited human genetic variation can contribute to important... continue reading >>

“These findings suggest a strong sensitization by the addition of metformin in obese population, suggesting that biochemical and molecular differences influence the treatment response.”

BUFFALO, NY- November 15, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March 31, 2023, entitled, “Obesity paradox and lung cancer, metformin-based therapeutic opportunity?”

In their recent editorial, researchers Pedro Barrios-Bernal, Norma Hernández-Pedro, Luis Lara-Mejía, and... continue reading >>

“This makes C/EBPβ an interesting pro-oncogenic player in AML, worthy of further studies.”

BUFFALO, NY- November 13, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.”

In this new paper, researcher Karl-Heinz Klempnauer from Westfälische-Wilhelms-Universität discusses recent studies on the role of transcription factor MYB in acute myeloid leukemia (AML). MYB has... continue reading >>

“In summary, this study reveals a molecular escape mechanism of mutated RTK-driven leukemic cells from SHP2 allosteric inhibition [...]”

BUFFALO, NY- November 8, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March 31, 2023, entitled, “Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors.”

The SH2 domain-containing tyrosine phosphatase 2 (SHP2) is a ubiquitously expressed non-receptor protein tyrosine... continue reading >>

“Our research study has demonstrated that poziotinib is highly potent in neratinib-resistant HER2 L755S lobular and ductal breast cancer models [...].”

BUFFALO, NY- November 6, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, “The uncharted role of HER2 mutant alleles in breast cancer.”

Somatic HER2 mutations are a novel class of therapeutic targets across different cancer types. Treatment with the tyrosine kinase inhibitor (TKI) neratinib... continue reading >>

“Besides being the most common, breast cancer is also a leading cause of cancer death in women worldwide.”

BUFFALO, NY- November 1, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 31, 2023, entitled, “FAAH inhibition ameliorates breast cancer in a murine model.”

Breast cancer is the leading cancer among females worldwide. Disease outcome depends on the hormonal status of the cancer and whether or not it is metastatic, but there is a need for more efficacious... continue reading >>

“This will open a novel therapeutic approach for targeting PMN-MDSC in cancer.”

BUFFALO, NY- October 30, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Neutrophil PAD4: how does it function in cancer beyond promoting NETosis?”

Expansion of pathologically activated immune-suppressive myeloid cells called myeloid-derived suppressor cells (MDSC) is one of the hallmarks of cancer. In most tumor types, MDSC are represented primarily by... continue reading >>

“[...] p53 acts in concert with other genes that alter the penetrance of tumor phenotypes and the modifiers differ among tissues.”

BUFFALO, NY- October 25, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Genetic modifiers of p53: opportunities for breast cancer therapies.”

Each day our cells encounter a wide range of genomic damage and the p53 protein arbitrates decisions of cell cycle arrest to allow repair of DNA or promote... continue reading >>

“Revealing the stem cell niche self-renewal dynamics is important not only for understanding tissue homeostasis but also for understanding the initiation of cancer [7].”

BUFFALO, NY- October 23, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 19, 2023, entitled, “Apoptotic cells may drive cell death in hair follicles during their regression cycle.”

Intravital microscopy in live mice has shown that the elimination of epithelial cells during hair follicle... continue reading >>

“[...] we hope that our findings will inform future decisions regarding treatment of liver disease.”

BUFFALO, NY- October 19, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on October 19, 2023, entitled, “GLS2 shapes ferroptosis in hepatocellular carcinoma.”

In their new editorial, researchers Sawako Suzuki, Divya Venkatesh, Tomoaki Tanaka, and Carol Prives from Columbia University discuss ferroptosis regulation of GLS2 as a potential therapeutic strategy against liver ... continue reading >>

“[...] ascertaining the mechanisms that enable metastatic spread can be transformational in our understanding of tumor progression and for future development of therapeutic interventions.”

BUFFALO, NY- October 18, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “The nuclear envelope and metastasis.”

In their new editorial, researchers Emily Hansen and James M. Holaska from Rowan University discuss nuclear morphology — one of the basic visual ... continue reading >>

“The paper revealed a critical role of GBP3 involving multiple [temozolomide] resistance mechanisms.”

BUFFALO, NY- October 17, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide.”

In their recent editorial, researchers Jun Ma, Ziyu Wang, Clark C. Chen, and Ming Li from the University of Minnesota discussed the... continue reading >>

“[...] our approach enables mechanistic studies of drug resistance with 3D cultures of primary cancer cells to develop and test treatments that suppress cancer [...].”

BUFFALO, NY- October 11, 2023 – A new research paper was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.”

Drug resistance is a major barrier against successful treatments of cancer patients. Gain of... continue reading >>

“Children diagnosed with these tumors have [...] a median survival of approximately 12 months.” 

BUFFALO, NY- October 9, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on October 4, 2023, entitled, “STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma.”

Pediatric H3K27M-mutant diffuse midline gliomas (DMGs), including those formerly classified as diffuse intrinsic pontine gliomas (DIPG), are uniformly lethal central nervous system... continue reading >>

“Given the potential challenges of directly inhibiting UGDH, therapeutic strategies may extend to targeting downstream pathways and upstream substrates.” 

BUFFALO, NY- October 4, 2023 – A new review paper was published in Oncotarget's Volume 14 on September 28, 2023, entitled, “UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.”

UDP-glucose-6-dehydrogenase (UGDH) is a cytosolic, hexameric enzyme that converts UDP-glucose to UDP-glucuronic acid (UDP-GlcUA), a key... continue reading >>

“DISE is effective against all cancers we tested.” 

BUFFALO, NY- October 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 25, 2023, entitled, “DISE, an ancient anti-cancer mechanism that senses mutational load in cancerous cells?”

In their new editorial, researchers Monal Patel and Marcus E. Peter from Northwestern University discuss a recent breakthrough in cancer therapy. Despite the multiple advances in therapy, cancer remains one of the most common... continue reading >>

“The balance between appropriate precautions and the harm of social isolation always requires a thorough appraisal.”

BUFFALO, NY- September 27, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 22, 2023, entitled, “Reassessing the risks and benefits of COVID-19 precautions in 2023.”

The COVID-19 pandemic has killed over one million Americans with many dying during the Omicron wave. By now most Americans have either had COVID-19 and/or been vaccinated against... continue reading >>

“These findings hold significant promise for improving our understanding of mechanistic pathways leading to EC in PCOS.”

BUFFALO, NY- September 25, 2023 – A new research paper was published in Oncotarget's Volume 14 on September 22, 2023, entitled, “Transcriptomic analysis identifies four novel receptors potentially linking endometrial cancer with polycystic ovary syndrome and generates a transcriptomic atlas.”

Polycystic Ovary Syndrome (PCOS) is associated with a 3 to 4-fold increased risk ... continue reading >>

“[...] we demonstrated that DPP4 inhibition increased sunitinib efficacy in DPP4-high RCC spheroids and DPP4 was upregulated in sunitinib-resistant RCC cells.”

BUFFALO, NY- September 20, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma.”

In their new editorial, researchers Kuniko Horie and Satoshi Inoue from Saitama Medical University and Tokyo ... continue reading >>

“This approach may allow clinicians to select the most effective therapeutic agents with real time in patients with pancreatic adenocarcinoma.” 

BUFFALO, NY- September 19, 2023 – A new research paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, “Real time ex vivo chemosensitivity assay for pancreatic adenocarcinoma.”

Patient-derived organoids (PDOs) and xenografts (PDXs) have been extensively studied for drug-screening. However, their usage is limited due to... continue reading >>

“With these new drugs now available in clinical practice, we expect HER2+/HER2-low BC patients with BMs to live longer and to live better.” 

BUFFALO, NY- September 13, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?”

In their new editorial, researchers Marta Vaz Batista, José Perez-Gracia, Inês Eiriz, Maria Gion, Antonio Llombart,... continue reading >>

“The future looks bright for patients with MET mutations and NSCLC.” 

BUFFALO, NY- September 11, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer.”

In their new editorial, researchers Mira Al Jaberi, Wolfgang Clough and Samir Dalia from Mercy Hospital discuss the MET gene. Several alterations in the MET gene were identified as targetable oncogenic changes leading to... continue reading >>

“The data in this paper suggest that even a small subpopulation of AIB1Δ4- expressing cells can enable cell invasion [...]” 

BUFFALO, NY- September 6, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on August 30, 2023, entitled, “Subpopulations of AIB1 isoform-expressing breast cancer cells enable invasion and metastasis.”

In their new editorial, researchers Amber J. Kiliti, Ghada M. Sharif, Anton Wellstein, and Anna T. Riegel from Georgetown University Medical Center... continue reading >>

“NeXT Dx incorporates a range of features and comprehensive genome variant detection methods that lead to improved disease management and possible enhanced clinical utility.”

BUFFALO, NY- August 30, 2023 – A new research paper was published in Oncotarget's Volume 14 on August 30, 2023, entitled, “Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay.”

In this new research paper, researchers Juan-Sebastian Saldivar, Jason Harris, Erin Ayash, Manqing Hong, Prateek Tandon,... continue reading >>

“[...] I hope that considering and testing the concept of adopted neoplastic cells will prove to be useful in explaining puzzling observations related to neoplasia [...]” 

BUFFALO, NY- August 29, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “Adopted neoplastic cells and the consequences of their existence.”

In this research perspective, researcher Yuri Lazebnik from Lerna Consulting begins by explaining a view that guides the bulk of ... continue reading >>

“We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” 

BUFFALO, NY- August 23, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 6, 2023, entitled, “A macrophage is a macrophage is a macrophage—in metastasis.”

In this new editorial, researcher Thomas T. Tapmeier from Monash University, Hudson Institute of Medical Research and University of Oxford discusses a... continue reading >>

“Our findings may provide a useful therapeutic approach for treating breast cancer patients who may suffer from early relapse and intrinsic resistance.”

BUFFALO, NY- August 21, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?”

A vast majority of breast cancers (~70%) are estrogen receptor-alpha positive (ER+), for which endocrine therapy is the common... continue reading >>

“These new findings evidence the necessity of more research in Gln metabolism to define the best therapeutic strategies for cancer patients.” 

BUFFALO, NY- August 16, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on August 10, 2023, entitled, “Inhibition of glutamine metabolism: acting on tumoral cells or on tumor microenvironment?”

Cancer cell growth and survival relies on metabolites and metabolic routes different from those used by healthy cells. Glucose and... continue reading >>

“We discuss existing clinical data on these surrogates of tumor burden and their potential in evaluating efficacy of immunotherapy in HPV-associated malignancies.” 

BUFFALO, NY- August 14, 2023 – A new review paper was published in Oncotarget's Volume 14 on August 10, 2023, entitled, “Peripheral surrogates of tumor burden to guide chemotherapeutic and immunotherapeutic strategies for HPV-associated malignancies.”

With the rapid adoption of immunotherapy into clinical practice for... continue reading >>

“[...] CDK9 inhibitors could play a role in future treatments of hematological diseases and could be a great ally when combined with other therapeutic approaches.”

BUFFALO, NY- August 9, 2023 – A new research perspective was published in Oncotarget's Volume 14 on August 7, 2023, entitled, “CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies.”

In their new perspective, researchers Daniel Morillo, Gala Vega and Victor Moreno from Hospital Fundación ... continue reading >>

“For the first time, descriptive and mechanistic data implicated the involvement of molecules of the RNA interference (RNAi) machinery in T-PLL’s leukemogenesis [...]"

BUFFALO, NY- August 7, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “AGO2 in T-prolymphocytic leukemia: its canonical and noncanonical deregulation and function.”

In their new editorial, researchers Till Braun, Hanna Klepzig and Marco Herling from University of Cologne and Univ... continue reading >>

“[...] our discovery of H3K27me3 as an epigenetic marker of radiation resistance in medulloblastoma has a potential to open new therapeutic avenues [...]”

BUFFALO, NY- August 2, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 12, 2023, entitled, “Targeting H3K27me3 loss in pediatric brain tumors - a perspective on epigenetically guided cancer therapy.”

High-grade tumors of the central nervous system, including medulloblastoma, ependymoma and DMG (diffuse midline... continue reading >>

“We have discussed in detail the clinical implications of ER in avoiding overtreatment and undertreatment in DCIS.”

BUFFALO, NY- August 1, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, “Multiclonality of ER expression in DCIS – Implications for clinical practice and future research.”

Estrogen receptor (ER) expression is not routinely evaluated in ductal carcinoma in situ (DCIS). This may be because the prognostic role of ER in DCIS was... continue reading >>

“We believe that KIAA0930 would be a novel cachexia therapeutic target.”

BUFFALO, NY- July 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, “The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells.”

Patients with cancer cachexia have a poor prognosis and impaired quality of life. Numerous studies using preclinical models have shown that inflammatory cytokines play an important role in... continue reading >>

“The results from this initial cohort support the integration of these biomarkers into prospective clinical trials.”

BUFFALO, NY- July 24, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 20, 2023, entitled, “Development of a multiplex assay to assess activated p300/CBP in circulating prostate tumor cells.”

Reduced SIRT2 deacetylation and increased p300 acetylation activity leads to a concerted mechanism of hyperacetylation at specific histone lysine sites... continue reading >>

“This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors.”

BUFFALO, NY- July 19, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma.”

The Hedgehog-GLI (HH/GLI) pathway is aberrantly activated in several types of cancer. Canonical HH/... continue reading >>

“The prognosis of recurrent/metastatic SS remains poor, highlighting the need for a novel therapeutic strategy.”

BUFFALO, NY- July 18, 2023 – A new case report was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Intrathoracic synovial sarcoma with BRAF V600E mutation.”

Synovial sarcoma (SS) is a highly malignant mesenchymal tumor that occurs mainly in adolescents and young adults. The treatment of SS is multimodal, involving surgery, radiotherapy and chemotherapy. The... continue reading >>

“Our data demonstrate that cetuximab plus radiotherapy represents an active treatment option for laCSCC, with manageable toxicity.”

BUFFALO, NY- July 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series.”

Treatment for locally advanced cutaneous squamous cell cancers (laCSCC) remains poorly defined. Most laCSCC... continue reading >>

“The mechanisms underlying the observed effects of progesterone on breast cancer outcomes are unclear.”

BUFFALO, NY- July 10, 2023 – A new research perspective was published in Oncotarget's Volume 14 on July 1, 2023, entitled, “Deciphering the mechanisms of action of progesterone in breast cancer.”

A practice-changing, randomized, controlled clinical study established that preoperative hydroxyprogesterone administration improves disease-free and overall survival in patients with... continue reading >>

“[...] we demonstrated that the combination of Nerofe and DOX exerts a synergistic effect during mCRC treatment [...]”

BUFFALO, NY- July 5, 2023 – A new research paper was published in Oncotarget's Volume 14 on July 1, 2023, entitled, “Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.”

Members of the rat sarcoma viral oncogene (RAS) subfamily KRAS are frequently mutated oncogenes in human cancers and have been identified in pancreatic ... continue reading >>

“The mechanism of the anti-metastatic activity of ERβ was investigated [...]”

BUFFALO, NY- July 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ERβ as a mediator of estrogen signaling in inflammatory breast cancer.”

In this new editorial, researchers Harika Nagandla and Christoforos Thomas from Houston Methodist Neal Cancer Center discuss inflammatory breast cancer (IBC)—a rare and aggressive form of breast cancer which accounts for 2–4%... continue reading >>

“Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.”

BUFFALO, NY- June 28, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability.”

The successful development of the BCL-2 inhibitor venetoclax, currently approved for chronic lymphocytic leukemia (CLL) ... continue reading >>

“Altogether, our results show that DPDT preferentially targets HCT116 colon cancer cells likely through DNA topoisomerase I poisoning.”

BUFFALO, NY- June 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on June 21, 2023, entitled, “Diphenyl ditelluride anticancer activity and DNA topoisomerase I poisoning in human colon cancer HCT116 cells.”

Diphenyl ditelluride (DPDT) is an organotellurium (OT) compound with pharmacological properties, including antioxidant,... continue reading >>

“[...] the experience with GITR targeting in patients may inform the development of either novel or next-generation immunotherapy approaches.”

BUFFALO, NY- June 21, 2023 – A new research perspective was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Targeting GITR in cancer immunotherapy – there is no perfect knowledge.”

In this new perspective, researchers Diwakar Davar and Roberta Zappasodi from the University of Pittsburgh Medical Center (UPMC), University of Pittsburgh,... continue reading >>

“[...] we found no impact of the addition of metformin to [androgen deprivation] therapy on risk of metabolic syndrome associated with castration therapy and no additional anti-tumor effects.”

BUFFALO, NY- June 20, 2023 – A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, “Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced... continue reading >>

Oncotarget's publisher, Impact Journals, is sponsoring Team Open Access in the annual cycling event to end cancer: The Ride for Roswell.

BUFFALO, NY- June 19, 2023 – The Ride for Roswell is one of the nation’s largest cycling events—hosted by Roswell Park Comprehensive Cancer Center—to raise awareness and funds for cancer research and patient care. This charity bike ride, based out of Buffalo, New York, has brought people together for 27 years to celebrate cancer survivors, pay tribute to lives ... continue reading >>

“ACSL4 has been demonstrated to play a pivotal role in both normal physiology as well as in a variety of disease states, including breast and other cancers.”

BUFFALO, NY- June 14, 2023 – A new review paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “ACSL4: biomarker, mediator and target in quadruple negative breast cancer.”

Breast cancer is a heterogeneous disease for which effective treatment depends on correct categorization of its molecular subtype. For the last... continue reading >>

“[...] we demonstrated the new acylfulvene compound LP-284 has anti-tumor activity including nanomolar potency in fifteen in vitro NHL cell lines and in vivo preclinical NHL models.”

BUFFALO, NY- June 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on June 12, 2023, entitled, “LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.”

Despite advances in therapies... continue reading >>

“[...] Src is a recognized oncotarget.”

BUFFALO, NY- June 9, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “Targeting the Src N-terminal regulatory element in cancer.”

The signaling pathways displayed by cancer cells are often composed of the same components as the physiological ones, yet the overall result is a pathological deregulation. In this new paper, researchers Betlem Mezquita, Marjorie Reyes-Farias and Miquel Pons from the Unive... continue reading >>

“[...] large multicenter prospective randomized trials are needed to provide the clinical evidence for the use of [chemotherapy] in second line and third-line post [immunotherapy] failure.”

BUFFALO, NY- June 7, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC).”

Lung cancer is the number one cause of mortality among all types of cancer worldwide. Its... continue reading >>

“The current study analyzed the correlation between BORIS mutations and the expression of the protein in breast cancer cases.”

BUFFALO, NY- June 5, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Association of mutation and expression of the brother of the regulator of imprinted sites (BORIS) gene with breast cancer progression.”

The brother of the regulator of imprinted sites (BORIS), 11 zinc-finger transcription factors, is a member of the... continue reading >>

“In this study, we present novel transcriptional dependencies between MALAT1 and MAPK-pathway-associated genes in melanoma.”

BUFFALO, NY- May 30, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, “Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.”

The long non-coding RNA (lncRNA) MALAT1 is a regulator of oncogenesis and cancer progression. MAPK-pathway upregulation is the main... continue reading >>

“[...] we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC [...].”

BUFFALO, NY- May 24, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 10, 2023, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.”

Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are highly... continue reading >>

“This research uncovers GPR141 as a stimulator of breast tumorigenesis and metastasis, making it a candidate target for breast cancer therapeutics.”

BUFFALO, NY- May 22, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 19, 2023, entitled, “G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis.”

Breast cancer morbidity is surging towards the peak in females across the globe. An... continue reading >>

“Here, we provide a brief overview of the status quo of targeting mitochondrial energy metabolism in glioblastoma and highlight a novel combination therapy.”

BUFFALO, NY- May 19, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Targeting cellular respiration as a therapeutic strategy in glioblastoma.”

While glycolysis is abundant in malignancies, mitochondrial metabolism is significant as well. Mitochondria harbor the enzymes relevant for... continue reading >>

Impact Journals (Oncotarget's publisher) is proud to participate at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes May 31–June 2, 2023, in Portland, Oregon.

BUFFALO, NY-May 17, 2023 – Impact Journals (Oncotarget's publisher) will be participating as an exhibitor at the Society for Scholarly Publishing (SSP) 45th Annual Meeting, which convenes on May 31–June 2, 2023, at the Oregon Convention Center & Hyatt Regency Portland in Portland, Oregon, USA. This year, the... continue reading >>

“[...] we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.”

BUFFALO, NY- May 16, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 12, 2023, entitled, “Development and implementation of an automated and highly accurate reporting process for NGS-based clonality testing.”

B and T cells undergo random recombination of the... continue reading >>

“[...] we consider some public molecular resources, including proteomics datasets, that may be leveraged to help identify gene candidates for therapeutic targeting in cancer.”

BUFFALO, NY- May 10, 2023 – A new research perspective was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Using cancer proteomics data to identify gene candidates for therapeutic targeting.”

Gene-level associations obtained from mass-spectrometry-based cancer proteomics datasets represent a resource... continue reading >>

“Importantly, the expression of several LY6 genes is elevated in UCEC [uterine corpus endometrial carcinoma] when compared to the expression in normal uterine tissue.”

BUFFALO, NY- May 8, 2023 – A new research paper was published in Oncotarget's Volume 14 on May 4, 2023, entitled, “Human LY6 gene family: potential tumor-associated antigens and biomarkers of prognosis in uterine corpus endometrial carcinoma.”

The human Lymphocyte antigen-6 (LY6) gene family has recently gained interest for... continue reading >>

“AL amyloidosis is a fatal disease and systemic therapy is required to prevent deposition of amyloid in other organs and prevent progressive organ failure.”

BUFFALO, NY- May 5, 2023 – A new review paper was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Systemic AL amyloidosis: current approach and future direction.”

In this review, researchers Maroun Bou Zerdan, Lewis Nasr, Farhan Khalid, Sabine Allam, Youssef Bouferraa, Saba Batool, Muhammad Tayyeb, Shubham Adroja,... continue reading >>

“Retinoids are known to inhibit tumor-promoting IL-6 production.”

BUFFALO, NY- May 3, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 26, 2023, entitled, “Disruption of retinol-mediated IL-6 expression in colon cancer-associated fibroblasts: new perspectives on the role of vitamin A metabolism.”

Colon cancer (CRC) is one of the most common malignancies and is a leading cause of cancer-related deaths worldwide. While the tumor microenvironment (TME)... continue reading >>

“A biomarker or set of biomarkers to inform on the individual progression risk would be beneficial to the patient and cost-effective for the healthcare system.”

BUFFALO, NY- May 2, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Crossroads: the role of biomarkers in the management of lumps in the breast.”

Here, Dr. Georg F. Weber from the University of Cincinnati Academic Health Center discusses a long-standing issue in women’s health: ... continue reading >>

“Our study emphasizes the importance of distinguishing between STAT3α and STAT3β proteins and their active forms when discussing STAT3-related cancer diagnosis and therapy.”

BUFFALO, NY- April 26, 2023 – A new research paper was published in Oncotarget's Volume 14 on April 24, 2023, entitled, “Differential silencing of STAT3 isoforms leads to changes in STAT3 activation.”

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor involved in multiple fundamental... continue reading >>

“[...] we found that blocking necroptosis leads to the inhibition of metastasis in mouse breast cancer models [...]”

BUFFALO, NY- April 24, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, “Tumor necroptosis promotes metastasis through modulating the interplay between tumor and host immunity.”

In this new editorial, researchers Zhaoshan Liu, Swati Choksi and Zheng-Gang Liu from the National Institutes of Health’s National Cancer Institute... continue reading >>

“To our knowledge, there are no studies evaluating the prognostic importance of CEA and Ca 19-9 in patients with DA [duodenal adenocarcinoma].”

BUFFALO, NY- April 18, 2023 – A new research paper was published in Oncotarget's Volume 14 on April 15, 2023, entitled, “Importance of carbohydrate antigen (CA 19-9) and carcinoembrionic antigen (CEA) in the prognosis of patients with duodenal adenocarcinoma: a retrospective single-institution cohort study.”

Duodenal adenocarcinoma (DA) is a rare... continue reading >>

“[...] long-term treatment with rapamycin slows down aging, a major risk factor for cancer [...]”

BUFFALO, NY- April 17, 2023 – A new research perspective was published in Oncotarget's Volume 14 on April 14, 2023, entitled, “Cancer prevention with rapamycin.”

The mTOR (Target of Rapamycin) pathway is involved in both cancer and aging. Furthermore, common cancers are age-related diseases, and their incidence increases exponentially with age. In his new research perspective, Mikhail V.... continue reading >>

“Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” 

BUFFALO, NY- April 12, 2023 – A new research paper was published in Oncotarget's Volume 14 on April 10, 2023, entitled, “A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.”

Overexpression of metabotropic glutamate receptor 1 (GRM1) has been implicated in the pathogenesis of multiple cancers. Riluzole, an inhibitor of glutamate release,... continue reading >>

“[...] the study of immunotherapy for treating triple negative breast cancer might still be at its early stages of development but is full of future promise.” 

BUFFALO, NY- April 10, 2023 – A new review paper was published in Oncotarget's Volume 14 on March 31, 2023, entitled, "Crosstalk between triple negative breast cancer and microenvironment."

Although many advances have been made in the treatment of breast cancer, for triple negative breast cancer (TNBC) these therapies have not... continue reading >>

“Beyond detection of cancer, CAFs are being actively pursued as targets for therapy.” 

BUFFALO, NY- April 5, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Cancer-associated fibroblasts: challenges and opportunities.”

Cancer-associated fibroblasts (CAFs) are a type of cell that plays a key role in the tumor microenvironment. While these cells have been extensively studied, their precise role in cancer development and progression... continue reading >>

Impact Journals (Oncotarget's publisher) is proud to participate at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes April 14-19 in Orlando, Florida.

BUFFALO, NY-April 4, 2023 – Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 from April 14-19 at the Orange County Convention Center in Orlando, Florida. This year, the AACR meeting theme is: “Advancing the Frontiers of Cancer... continue reading >>

“Cortactin (also known as EMS1 or CTTN) is expressed broadly in a variety of cancers [...]” 

BUFFALO, NY- April 4, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.”

In this editorial, researchers Kamrul Hasan and Thomas J. Kipps from the University of California discuss cortactin—an intracellular cytoskeletal protein that can undergo tyrosine phosphorylation upon... continue reading >>

“In the present study, we found that downregulation of angulin-1/LSR induced malignancy via upregulation of EGF-dependent CLDN-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma.” 

BUFFALO, NY- March 29, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.”

Abnormal... continue reading >>

"[...] mutations in G-proteins have been associated in the progress of several cancers [...]”

BUFFALO, NY- March 28, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.”

Finding effective therapies against cancers driven by mutant and/or overexpressed hyperactive G-proteins remains an area of active research.... continue reading >>

“This study was designed to increase the knowledge on the potential of GPCs and in particular GPC1 as a biomarker in cancer diagnosis and prognosis.” 

BUFFALO, NY- March 22, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 21, 2023, entitled, “Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.”

Glypicans (GPC1-6) are associated with tumorigenic processes and their involvement in neoplastic behavior... continue reading >>

“We are very enthusiastic about these initiatives and the recent rate of discoveries in OSA, and hopeful that they will bring actionable targets for OSA.” 

BUFFALO, NY- March 20, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Unlocking the potential of molecular-driven stratification for osteosarcoma treatment and prognosis.”

Over the last 40 years, the complex genetic landscape, the heterogeneity of the microenvironment and the cell... continue reading >>

“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].”

BUFFALO, NY- March 14, 2023 – A new research paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (MTAP) loss.”

Homozygous deletion of methylthioadenosine phosphorylase (MTAP)... continue reading >>

“Selective protection of normal cells may transform therapy of cancer.” 

BUFFALO, NY- March 13, 2023 – A new review paper was published in Oncotarget's Volume 14 on March 11, 2023, entitled, “Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells.”

Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. In his latest review, Mikhail V. Blagosklonny, M.D., Ph.D., from Roswell Park Comprehensive Cancer Center discusse... continue reading >>

“Overall, this research proposes a new paradigm on how AR-independent PCa can drive tumor traits by exploiting mitochondrial signaling pathways [...]” 

BUFFALO, NY- March 8, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on February 25, 2023, entitled, “Mitochondria engage the integrated stress response to promote tumor growth.”

In this new editorial, researchers Dillon P. Boulton and M. Cecilia Caino from the University of Colorado School of Medicine discussed prostate... continue reading >>

“In the last several years, the Hemoglobin, Albumin, Lymphocyte, Platelet Score (HALP) has emerged in the literature as a new prognostic biomarker [...]” 

BUFFALO, NY- March 6, 2023 – A new review paper was published in Oncotarget's Volume 14 on February 25, 2023, entitled, “What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types.”

Since its inception, the Hemoglobin, Albumin, Lymphocyte, Platelet... continue reading >>

“In summary, both articles by Yi et al. emphasized the significance of non-canonical functions of EZH2 during PCa [prostate cancer] development [...]” 

BUFFALO, NY- March 3, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Unveiling the non-canonical functions of EZH2 in prostate cancer.”

Prostate cancer (PCa) is ranked as the second leading cause of cancer-related death among American men excluding skin cancer. In this new editorial,... continue reading >>

“The definition of low-risk WNT-pathway medulloblastoma may need to be refined in light of recent clinical data and newer biological information.” 

BUFFALO, NY- February 27, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 7, 2023, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?”

Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups - WNT,... continue reading >>

“Together, this work highlights the need to investigate different breakpoints of fusion proteins, as they may potentially lack the necessary biological activity required for oncogenesis, ultimately leading to misidentification of presumed oncogenes.” 

BUFFALO, NY- February 23, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 11, 2023, entitled, “Oncogenic driver FGFR3-TACC3 requires five coiled-coil heptads for activation and disulfide bond formation for stability... continue reading >>

“Basic functions of ATR classify it in the category of tumor suppressor genes but further studies show that its role is more complex in the context of cancer.” 

BUFFALO, NY- February 21, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 7, 2023, entitled, “The ‘extreme phenotype approach’ applied to male breast cancer allows the identification of rare variants of ATR as potential breast cancer susceptibility alleles.”

In oncogenetics, some patients could be... continue reading >>

“In this study, the ICPI [inflammation-combined prognostic index] was devised as a novel predictive index of prognosis, and its usefulness was clarified.” 

BUFFALO, NY- February 14, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 31, 2023, entitled, “Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer.”

In vivo inflammatory responses are involved in cancer growth, invasion and metastasis, and the involvement... continue reading >>

“[...] we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” 

BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February 2, 2023, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC).”

TP53 mutant head and neck squamous cell carcinoma (HNSCC) patients exhibit poor clinical outcomes with 50–60%... continue reading >>

“CD200 expression is reported across most cancer types [...]” 

BUFFALO, NY- February 7, 2023 – A new research perspective was published in Oncotarget's Volume 14 on February 4, 2023, entitled, “The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.”

CD200 is an immunoregulatory cell surface ligand with proven pro-tumorigenic credentials via its ability to suppress CD200 receptor (CD200R)-expressing anti-tumor immune function. This definitive role ... continue reading >>

“The current analysis provides updated results for these lymphoma patients with extended follow-up.” 

BUFFALO, NY- February 1, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 26, 2023, entitled, “Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).”

In this new research paper, researchers Leo I. Gordon, Reem Karmali, Jason B.... continue reading >>

“Immunotherapies, including oncolytic virotherapy, offer novel, targeted approaches to treat brain tumors with increased efficacy and reduced toxicity [5].” 

BUFFALO, NY- January 26, 2023 – A new research perspective was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Intraventricular immunovirotherapy; a translational step forward.”

In this new perspective, researchers Joshua D. Bernstock, Sarah Blitz, Kyung-Don Kang, and Gregory K. Friedman from Harvard Medical School, Mass... continue reading >>

“The andiroba extract in wounds provides acceleration in healing process, with increase of contraction rate and local re-epithelialization, resulting in the complete closure of wounds [52].” 

BUFFALO, NY- January 24, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “The chromatographic constitution of andiroba oil and its healing effects, compared to the LLLT outcomes, in oral mucositis induced in golden Syrian hamsters: a new treatment option.”... continue reading >>

“Taken together, these findings provide a strong rationale for potently and selectively targeting of CD74 in patients with B-NHL [B-cell non-Hodgkin lymphoma].”

BUFFALO, NY- January 17, 2023 – A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, “Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001.”

Overexpression of CD74, a type II transmembrane glycoprotein involved in MHC class II antigen presentation, has been... continue reading >>

“The goal of the present study was to determine the therapeutic potential of 15d-PMJ2 against melanoma by gaining insight into molecular mechanisms underlying its apoptotic activity.” 

BUFFALO, NY- January 12, 2023 – A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Calcium signaling induced by 15-deoxy-prostamide-J2 promotes cell death by activating PERK, IP3R, and the mitochondrial permeability transition pore.”

Melanoma is the deadliest form of... continue reading >>

“In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” 

BUFFALO, NY- January 11, 2023 – A new research paper was published in Oncotarget's Volume 13 on December 29, 2022, entitled, “Impact of Covid-19 on the management of patients with metastatic melanoma.”

The Covid-19 pandemic created new uncertainties in the management of metastatic melanoma patients. In particular, the impact of... continue reading >>

“One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” 

BUFFALO, NY- January 5, 2023 – A new research paper was published in Oncotarget's Volume 13 on December 20, 2022, entitled, “Resistance of MMTV-NeuT/ATTAC mice to anti-PD-1 immune checkpoint therapy is associated with macrophage infiltration and Wnt pathway expression.”

One of the central challenges for cancer therapy is the identification of factors in the tumor... continue reading >>